Evidence map›Paper›PMID 30074079›Full record

ArticleCalcified tissue international2018

VWC2 Increases Bone Formation Through Inhibiting Activin Signaling.

Ahmad Almehmadi, Yoshio Ohyama, Masaru Kaku, Ahmed Alamoudi, Dina Husein, Michitsuna Katafuchi, Yuji Mishina, Yoshiyuki Mochida

Open access · greenAbstract read
In one paragraph

Article in Calcified tissue international, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.4field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 3 countries.

Ahmad AlmehmadiDepartment of Molecular and Cell Biology, Boston University, Henry M. Goldman School of Dental Medicine, Boston, MA, USA.
Yoshio OhyamaDepartment of Molecular and Cell Biology, Boston University, Henry M. Goldman School of Dental Medicine, Boston, MA, USA.
Masaru KakuDivision of Bio-Prosthodontics, Niigata University Graduate School of Medical and Dental Sciences, Niigata, Japan.
Ahmed AlamoudiDepartment of Molecular and Cell Biology, Boston University, Henry M. Goldman School of Dental Medicine, Boston, MA, USA.
Dina HuseinDepartment of Molecular and Cell Biology, Boston University, Henry M. Goldman School of Dental Medicine, Boston, MA, USA.
Michitsuna KatafuchiDepartment of Oral Rehabilitation, Section of Fixed Prosthodontics, Fukuoka Dental College, Fukuoka, Japan.
Yuji MishinaDepartment of Biologic and Materials Sciences, School of Dentistry, University of Michigan, Ann Arbor, MI, USA.
Yoshiyuki MochidaDepartment of Molecular and Cell Biology, Boston University, Henry M. Goldman School of Dental Medicine, Boston, MA, USA. mochida@bu.edu.
Boston University · USKing Abdulaziz University · SAFukuoka Dental College · JPNiigata University · JPUniversity of Michigan–Ann Arbor · US

Funding

Molecular pathogenesis of craniosynostosis caused by enhanced BMP signalingR01DE020843 · NIDCR · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI MISHINA, YUJI · 2010 to 2019
$4.9M
EVC2: A novel modulator in tooth developmentR01DE019527 · NIDCR · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MOCHIDA, YOSHIYUKI · 2009 to 2013
$2.0M
Role of Vwc2-assisted activin signaling in bone formationR21AR057451 · NIAMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI MOCHIDA, YOSHIYUKI · 2009 to 2010
$398k
NIAMS NIH HHS R21 AR057451NIDCR NIH HHS R01 DE019527NIDCR NIH HHS R01 DE020843
6 · The paper itself

Abstract

By a bioinformatics approach, we have identified a novel cysteine knot protein member, VWC2 (von Willebrand factor C domain containing 2) previously known as Brorin. Since Brorin has been proposed to function as a bone morphogenetic protein (BMP) antagonist, we investigated the binding of Brorin/VWC2 to several BMPs; however, none of the BMPs tested were bound to VWC2. Instead, the βA subunit of activin was found as a binding partner among transforming growth factor (TGF)-β superfamily members. Here, we show that Vwc2 gene expression is temporally upregulated early in osteoblast differentiation, VWC2 protein is present in bone matrix, and localized at osteoblasts/osteocytes. Activin A-induced Smad2 phosphorylation was inhibited in the presence of exogenous VWC2 in MC3T3-E1 osteoblast cell line and primary osteoblasts. The effect of VWC2 on ex vivo cranial bone organ cultures treated with activin A was investigated, and bone morphometric parameters decreased by activin A were restored with VWC2. When we further investigated the biological mechanism how VWC2 inhibited the effects of activin A on bone formation, we found that the effects of activin A on osteoblast cell growth, differentiation, and mineralization were reversed by VWC2. Taken together, a novel secretory protein, VWC2 promotes bone formation by inhibiting Activin-Smad2 signaling pathway.

Indexed as

AnimalsCell DifferentiationExtracellular Matrix ProteinsHEK293 CellsHumansInhibin-beta SubunitsMiceMice, Inbred C57BLNerve Tissue ProteinsOsteoblastsOsteogenesisSignal TransductionExtracellular Matrix Proteinsinhibin beta A subunitInhibin-beta SubunitsNerve Tissue ProteinsVwc2 protein, mouseActivin ABone formationCalvariaOsteoblastsVon Willebrand factor C domain containing 2 (VWC2)

Identifiers

PMID30074079
PMCPMC6549224
OpenAlexW2885924860

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.